Physician profile
Valeri Kraskovsky
NPI 1396155529
$8,291.79
in general payments reported to CMS, 2019-2025
27 companies · $1,172 in 2025
The $1,172 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $284 · 2023: $5,032 · 2024: $1,804 · 2025: $1,172.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,740 · Education: $3,016 · Travel and Lodging: $787 · Consulting Fee: $465.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,740.20 |
| Education | $3,016.24 |
| Travel and Lodging | $786.56 |
| Consulting Fee | $465.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $4,135.11 | 2023-2025 | Ion, Da Vinci Surgical System |
| Astrazeneca Pharmaceuticals Lp | $1,171.67 | 2022-2025 | Tagrisso, Fasenra, Airsupra |
| Glaxosmithkline, LLC. | $919.03 | 2022-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Grifols USA, LLC | $272.11 | 2022-2025 | Prolastin-C Liquid |
| Boehringer Ingelheim Pharmaceuticals, INC. | $268.06 | 2022-2025 | Ofev, Jascayd, Stiolto Respimat |
| Pentax of America, INC. | $212.00 | 2024 | Pentax Medical, Inspira, C2 Cryoballoon Focal Controller |
| Genzyme Corporation | $182.22 | 2022-2025 | |
| Noah Medical Corporation | $151.62 | 2024 | Galaxy |
| Regeneron Healthcare Solutions, INC. | $145.86 | 2023-2025 | Dupixent |
| Amgen INC. | $131.50 | 2022-2025 | Tezspire |
| Mylan Specialty L.P. | $121.49 | 2023-2024 | Yupelri |
| Insmed, INC. | $71.81 | 2024-2025 | Arikayce, Brinsupri |
| Viatris Specialty LLC | $54.72 | 2025 | Yupelri |
| Electromed, INC. | $54.18 | 2024-2025 | Smartvest |
| Takeda Pharmaceuticals U.S.A., INC. | $49.09 | 2022-2025 | Glassia |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $45.87 | 2022-2023 | Wegovy |
| Fujifilm Healthcare Americas Corporation | $43.27 | 2024 | Fujifilm |
| Galvanize Therapeutics, INC | $34.42 | 2024 | Aliya System |
| Baxter Healthcare | $32.75 | 2023 | Hillrom - Life 2000 Ventilation System |
| Vifor Pharma, INC. | $31.22 | 2025 | Veltassa |
| United Therapeutics Corporation | $27.77 | 2024 | Tyvaso |
| Pfizer INC. | $27.55 | 2023 | |
| Actelion Pharmaceuticals US, INC. | $26.45 | 2025 | Opsumit, Uptravi |
| Inogen, INC. | $26.18 | 2023 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Philips North America LLC | $19.97 | 2022 | |
| Amarin Pharma, INC. | $19.39 | 2023 | |
| Verona Pharma, INC. | $16.48 | 2025 | Ohtuvayre |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Valeri Kraskovsky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.